Report LibraryAll Reports
Datamonitor Healthcare Oncology Disease Analysis: HR+/HER2- Breast Cancer
September 09, 2021
CDK4/6 inhibitors remain the standard treatment for advanced and metastatic HR+/HER2- patients. Datamonitor Healthcare expects their uptake to increase significantly over the forecast period as Verzenio and Kisqali are projected to receive strategic label expansions into the adjuvant treatment setting for early-stage HR+/HER2- breast cancer patients. Verzenio is set to be the first of these therapies approved in early breast cancer, with US and EU regulatory decisions expected towards the end of 2021. Submissions were based on positive results from the Phase III monarchE trial. Ibrance is not forecasted to receive a similar approval after the failure of the PALLAS and PENELOPE-B trials.
The PARP inhibitors have become the standard option for gBRCAm+ breast cancer patients. Despite their efficacy in this population, their overall commercial potential will remain limited in the near term by their positioning in this niche segment. Expansion into the adjuvant setting for earlier-stage disease will improve their outlook, beginning with Lynparza, which improved the risk of invasive breast cancer recurrence, second cancer, or death by 42% over placebo in the Phase III OlympiA trial.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Breast Cancer|